Scarica l'app Stockscreener
3.11
1.63%
0.05
Dopo l'orario di chiusura:
3.08
-0.03
-0.96%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Fund Flows: Is Recursion Pharmaceuticals Inc forming a double bottom2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) latest stock news and headlines - au.finance.yahoo.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance Singapore
Does AI Data Deal And New CMO Hire Change The Bull Case For Recursion (RXRX)? - Sahm
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know - MSN
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance UK
Director at Recursion (NASDAQ: RXRX) awarded 3,268 shares - Stock Titan
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge - Sahm
1 Beaten-Down AI Stock to Buy and 1 to Avoid - Yahoo Finance
Recursion names Vicki Goodman as CMO - MSN
Citeline expands partnership with Recursion for clinical trials - investing.com
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform - GlobeNewswire Inc.
2 AI Healthcare Stocks to Buy Right Now - The Globe and Mail
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $2.98 By Investing.com - Investing.com Australia
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - Yahoo Finance
Recursion Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
RXRX Faces Stock Strain as Bank of America Slashes Price Target - StocksToTrade
Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Recursion Pharmaceuticals (RXRX) Has Fallen 16.5% Since Previous Earnings Report: Is a Recovery Possible? - Bitget
Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound? - finance.yahoo.com
Recursion Pharmaceuticals stock hits 52-week low at $2.98 - Investing.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
RXRX Stock: Why Did Nvidia Offload AI Drug Developer Recursion? - cmcmarkets.com
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus - Sahm
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Recent Share Price Weakness And Split Fair Value Views - Yahoo Finance
Recursion Pharmaceuticals Appoints Vicki Goodman, M.D. as Chief Medical Officer to Advance Clinical Pipeline and AI-Driven Drug Development 1 - Minichart
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals Names New Chief Medical Officer - TipRanks
Recursion appoints Vicki Goodman as Chief Medical Officer; David Mauro to transition to advisor - tradingview.com
Vicki Goodman to become Recursion (NASDAQ: RXRX) chief medical officer - Stock Titan
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals (RXRX) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer - marketscreener.com
Recursion taps former FDA reviewer Vicki Goodman as chief medical officer - Stock Titan
Assessing Recursion Pharmaceuticals (RXRX) Valuation After Prolonged Share Price Weakness - Sahm
Recursion Pharmaceuticals Stock (RXRX) Opinions on Roche's AI Drug Development Commitment - Quiver Quantitative
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):